Zoely

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

Nomegestrol acetate, estradiol

Available from:

Theramex Ireland Limited

ATC code:

G03AA14

INN (International Name):

nomegestrol, estradiol

Therapeutic group:

- Ormoni tas-sess u modulaturi ta ' l-ġenitali-sistema,

Therapeutic area:

Kontraċezzjoni

Therapeutic indications:

Oral contraception,.

Product summary:

Revision: 23

Authorization status:

Awtorizzat

Authorization date:

2011-07-26

Patient Information leaflet

                                30
B. FULJETT TA’ TAGĦRIF
31
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-UTENT
ZOELY 2.5 MG/1.5 MG PILLOLI MIKSIJA B’RITA
nomegestrol acetate/estradiol
AFFARIJIET IMPORTANTI LI GĦANDEK TKUN TAF DWAR IL-KONTRAĊETTIVI
KKOMBINATI TAL-ORMONI (CHCS -
_COMBINED HORMONAL CONTRACEPTIVES_):
•
Huma wieħed mill-metodi ta’ kontraċezzjoni riversibbli l-aktar
affidabbli jekk jintużaw kif
suppost.
•
Huma jżidu kemxejn ir-riskju li jkollok tagħqid ta’ demm fil-vini
u fl-arterji, speċjalment fl-
ewwel sena jew meta terġa’ tibda tuża kontraċettiv ikkombinat
tal-ormoni mill-ġdid wara waqfa
ta’ 4 ġimgħat jew aktar.
•
Jekk jogħġbok kun attenta u ara lit-tabib tiegħek jekk taħseb li
jista’ jkollok sintomi ta’ tagħqid
ta’ demm (ara sezzjoni 2 “Tagħqid tad-demm”).
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TUŻA DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib, lill-ispiżjar jew
lill-infermier tiegħek.
-
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara, anke jekk għandhom l-istess sinjali ta’
mard bħal tiegħek.
-
Jekk ikollok xi effett sekondarju kellem lit-tabib, lill-ispiżjar jew
lill-infermier tiegħek. Dan
jinkludi xi effett sekondarju possibbli li mhuwiex elenkat f’dan
il-fuljett. Ara sezzjoni 4.
F’DAN IL-FULJETT
1.
X’inhu Zoely u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tuża Zoely
3.
Kif għandek tuża Zoely
4.
Effetti sekondarji possibbli
5.
Kif taħżen Zoely
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU ZOELY U GĦALXIEX JINTUŻA
Zoely hu pillola kontraċettiva li tintuża biex tiġi evitata
t-tqala.
•
L-24 pillola bajda miksija b’rita kollha huma pilloli attivi li
fihom ammont żgħir ta’ żewġ
ormoni differenti tan-nisa. Dawn huma nomegestrol acetate
(progestogen) u estradiol (estroġen).
•
L-4 pilloli sofor miksija b’rita hum
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Zoely 2.5 mg/1.5 mg pilloli miksija b’rita
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Kull pillola bajda attiva fiha 2.5 mg ta’ nomegestrol acetate u 1.5
mg ta’ estradiol (bħala hemihydrate).
Kull pillola safra tal-plaċebo ma fihiex sustanzi attivi.
Eċċipjenti b’effett magħruf
Kull pillola bajda attiva fiha 57.7 mg ta’ lactose monohydrate.
Kull pillola safra tal-plaċebo fiha 61.8 mg ta’ lactose
monohydrate.
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola miksija b’rita (pillola).
Il-pillola attiva hija bajda, tonda u b’kodiċi ‘ne’ fuq
iż-żewġ naħat.
Il-pillola tal-plaċebo hija safra, tonda u bkodiċi ‘p’ fuq
iż-żewġ naħat.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Kontraċezzjoni orali.
Meta tittieħed id-deċiżjoni li jiġi preskritt Zoely għandhom
jitqiesu l-fatturi attwali ta’ riskju tal-mara
individwali, b’mod partikolari dawk ta’ tromboemboliżmu fil-vini
(VTE -
_venous thromboembolism_
),
u kif ir-riskju ta’ VTE b’Zoely jikkumpara ma’ dak ta’
kontraċettivi kkombinati tal-ormoni (CHCs -
_combined hormonal contraceptives_
) oħra (ara sezzjonijiet 4.3 u 4.4).
4.2
POŻOLOĠIJA U METODU TA’ KIF GĦANDU JINGĦATA
Pożoloġija
Pillola waħda għandha tittieħed kuljum għal 28 jum konsekuttiv.
Kull pakkett jibda b’24 pillola attiva
bajda segwiti minn 4 pilloli sofor tal-plaċebo. Pakkett sussegwenti
għandu jinbeda minnufih wara li
jkun intemm il-pakkett ta’ qabel, mingħajr l-ebda waqfien
fit-teħid tal-pillola ta’ kuljum u
rrispettivament mill-preżenza jew assenza ta’ ħruġ ta’ demm
meta tieqaf tieħu l-mediċina. Il-ħruġ ta’
demm meta tieqaf tieħu l-mediċina ġeneralment jibda fit-2-3 jum
wara t-teħid tal-aħħar pillola bajda u
għandu mnejn ma jispiċċax qabel ma jkun inbeda l-pakkett li jmiss.
Ara ‘Kontroll taċ-ċiklu’ f’sezzjoni
4.4
_ _
_Popolazzjonijiet speċjali _
_ _
_Indeboliment tal
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 16-12-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 16-12-2022
Public Assessment Report Public Assessment Report Bulgarian 17-05-2016
Patient Information leaflet Patient Information leaflet Spanish 16-12-2022
Public Assessment Report Public Assessment Report Spanish 17-05-2016
Patient Information leaflet Patient Information leaflet Czech 16-12-2022
Public Assessment Report Public Assessment Report Czech 17-05-2016
Patient Information leaflet Patient Information leaflet Danish 16-12-2022
Public Assessment Report Public Assessment Report Danish 17-05-2016
Patient Information leaflet Patient Information leaflet German 16-12-2022
Public Assessment Report Public Assessment Report German 17-05-2016
Patient Information leaflet Patient Information leaflet Estonian 16-12-2022
Public Assessment Report Public Assessment Report Estonian 17-05-2016
Patient Information leaflet Patient Information leaflet Greek 16-12-2022
Public Assessment Report Public Assessment Report Greek 17-05-2016
Patient Information leaflet Patient Information leaflet English 16-12-2022
Public Assessment Report Public Assessment Report English 17-05-2016
Patient Information leaflet Patient Information leaflet French 16-12-2022
Public Assessment Report Public Assessment Report French 17-05-2016
Patient Information leaflet Patient Information leaflet Italian 16-12-2022
Public Assessment Report Public Assessment Report Italian 17-05-2016
Patient Information leaflet Patient Information leaflet Latvian 16-12-2022
Public Assessment Report Public Assessment Report Latvian 17-05-2016
Patient Information leaflet Patient Information leaflet Lithuanian 16-12-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 16-12-2022
Public Assessment Report Public Assessment Report Lithuanian 17-05-2016
Patient Information leaflet Patient Information leaflet Hungarian 16-12-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 16-12-2022
Public Assessment Report Public Assessment Report Hungarian 17-05-2016
Patient Information leaflet Patient Information leaflet Dutch 16-12-2022
Public Assessment Report Public Assessment Report Dutch 17-05-2016
Patient Information leaflet Patient Information leaflet Polish 16-12-2022
Public Assessment Report Public Assessment Report Polish 17-05-2016
Patient Information leaflet Patient Information leaflet Portuguese 16-12-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 16-12-2022
Public Assessment Report Public Assessment Report Portuguese 17-05-2016
Patient Information leaflet Patient Information leaflet Romanian 16-12-2022
Public Assessment Report Public Assessment Report Romanian 17-05-2016
Patient Information leaflet Patient Information leaflet Slovak 16-12-2022
Public Assessment Report Public Assessment Report Slovak 17-05-2016
Patient Information leaflet Patient Information leaflet Slovenian 16-12-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 16-12-2022
Public Assessment Report Public Assessment Report Slovenian 17-05-2016
Patient Information leaflet Patient Information leaflet Finnish 16-12-2022
Public Assessment Report Public Assessment Report Finnish 17-05-2016
Patient Information leaflet Patient Information leaflet Swedish 16-12-2022
Public Assessment Report Public Assessment Report Swedish 17-05-2016
Patient Information leaflet Patient Information leaflet Norwegian 16-12-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 16-12-2022
Patient Information leaflet Patient Information leaflet Icelandic 16-12-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 16-12-2022
Patient Information leaflet Patient Information leaflet Croatian 16-12-2022
Public Assessment Report Public Assessment Report Croatian 17-05-2016

View documents history